CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corcept Therapeutics Inc (CORT) does not present a strong buy opportunity for a beginner investor with a long-term focus at this time. While the technical indicators and analyst ratings are generally positive, insider selling and ongoing legal investigations create uncertainty. The lack of recent Intellectia Proprietary Trading Signals further diminishes the urgency to act. Holding or waiting for clearer signals is recommended.
The technical indicators suggest a mixed outlook. The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 57.635, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are at 79.2 (pivot), 84.098 (R1), and 74.303 (S1). The stock closed at 79.91, slightly above the pivot level, but the price trend is not strongly directional.
Resubmission of the NDA for relacorilant with positive trial data and a six-month review period.
Recent analyst upgrades and raised price targets, with confidence in the company's regulatory pathway and new drug approvals.
Bullish moving averages and low put-call ratios in options trading.
Insider selling has increased by 271.06% in the last month, signaling potential lack of confidence from within the company.
Legal investigations into potential fiduciary breaches by executives, which could harm shareholder value.
Stock trend analysis indicates potential short-term declines (-1.58% in the next week, -4.25% in the next month).
No financial data available for the latest quarter, making it difficult to assess growth trends or profitability.
Analyst sentiment is broadly positive, with multiple upgrades and raised price targets. Recent updates highlight confidence in the company's drug pipeline, particularly the resubmission of relacorilant and the commercial availability of Lifyorli. Price targets range from $72 to $135, suggesting significant upside potential.
